摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-乙基-8-喹啉胺 | 46166-12-5

中文名称
N-乙基-8-喹啉胺
中文别名
——
英文名称
N-ethylquinolin-8-amine
英文别名
——
N-乙基-8-喹啉胺化学式
CAS
46166-12-5
化学式
C11H12N2
mdl
MFCD11141647
分子量
172.23
InChiKey
KQQJLXPIKPOAOD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.181
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-乙基-8-喹啉胺吡啶叔丁基过氧化氢 作用下, 以 癸烷 为溶剂, 反应 1.5h, 以82%的产率得到N-ethyl-5-iodoquinolin-8-amine
    参考文献:
    名称:
    室温下杂芳烃的卤素键辅助电子催化原子经济碘化
    摘要:
    在室温下原子经济条件下,首次开发了卤素键辅助的电子催化的杂芳烃碘化反应。仅用0.55当量的碘和0.50当量的过氧化物就能成功进行碘化。动力学研究表明,在底物和碘之间不存在卤素键的情况下,该反应难以捉摸。卤素键的形成,其在降低该反应的活化势垒中的重要性,反应混合物中自由基中间体的存在以及反应的区域选择性已通过数个对照实验,光谱分析和量子化学计算得到了证明。
    DOI:
    10.1021/acs.joc.9b00174
  • 作为产物:
    参考文献:
    名称:
    Yasuye; Yasukawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1946, vol. 66, p. 4
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Copper-Catalyzed C5–H Sulfenylation of Unprotected 8-Aminoquinolines Using Sulfonyl Hydrazides
    作者:Qing Yu、Yiming Yang、Jie-Ping Wan、Yunyun Liu
    DOI:10.1021/acs.joc.8b01658
    日期:2018.9.21
    unprotected 8-aminoquinolines and sulfonyl hydrazides is achieved via the catalysis of CuI. The reactions are hypothesized to proceed via the Cu(I)–Cu(II)–Cu(I) catalytic processes induced by aerobic oxidation and single-electron transfer on the Cu(II)–8-aminoquinoline complex. This work discloses an unprecedented step-efficient method for the synthesis of C5-sulfenylated 8-aminoquinolines bearing a useful free
    使用未保护的8-氨基喹啉和磺酰基酰肼合成C5-亚磺酰基化的8-氨基喹啉是通过CuI的催化来实现的。假设反应是通过有氧氧化和单电子转移在Cu(II)-8-氨基喹啉络合物上诱导的Cu(I)-Cu(II)-Cu(I)催化过程进行的。这项工作公开了一种空前的步骤高效的方法,用于合成带有有用的游离NH 2基团的C5-亚磺酰基化的8-氨基喹啉。
  • Identification of benzenesulfonamide quinoline derivatives as potent HIV-1 replication inhibitors targeting Rev protein
    作者:Fudi Zhong、Guannan Geng、Bing Chen、Ting Pan、Qianwen Li、Hui Zhang、Chuan Bai
    DOI:10.1039/c4ob02247e
    日期:——
    immunodeficiency virus type 1 (HIV-1) Rev protein facilitates the export of viral RNA from nucleus to cytoplasm, which is a key step in HIV-1 pathogenesis and transmission. In this study, we have screened a commercial library and identified the hit compound 1 bearing a benzenesulfonamide quinoline scaffold that inhibited Rev activity and HIV-1 infectivity. Compounds bearing this scaffold were synthesized and
    1型人类免疫缺陷病毒(HIV-1)Rev蛋白促进病毒RNA从细胞核到细胞质的输出,这是HIV-1发病机理和传播的关键步骤。在这项研究中,我们筛选了一个商业文库,并鉴定了带有抑制Rev活动和HIV-1感染性的带有苯磺酰胺喹啉骨架的命中化合物1。合成带有该支架的化合物并研究其SAR。我们鉴定出具有低毒性和有效活性的化合物20,可通过影响Rev功能来抑制HIV-1复制。
  • [EN] 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] DERIVES DE BENZIMIDAZOLE SUBSTITUES EN 5- OU 6- UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS RESPIRATOIRE SYNCITIAL
    申请人:TIBOTEC PHARM LTD
    公开号:WO2005058874A1
    公开(公告)日:2005-06-30
    The present invention concerns 5- or 6-substituted-benzimidazole derivatives having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein Q is Ar2, R6, pyrrolidinyl substituted with R6, piperidinyl substituted with R6 or homopiperidinyl substituted with R6, G is a direct bond or optionally substituted C1-10alkanediyl; R1 is Arl or a monocyclic or bicyclic heterocycle; one of R 2a and R2b is cyanoCl-6alkyl, cyanoC2-6alkenyl, Ar3Cl-6alkyl, Het­-C1-6alky1, N(R8aR8b)Cl-6alkyl, Ar3C2-6alkenyl, Het-C2-6alkenyl, Ar3 aminoCl-6alkyl, Het­aminoCl-6alkyl, Ar3thioC1-6 alkyl, Het-thioC1-6alkyl, Ar3sulfonylC1-6 alkyl, Het­sulfonylC1-6alkyl, Ar3aminocarbonyl, Het-aminocarbonyl, Ar3(CH2)naminocarbonyl, Het-(CH2)naminocarbonyl, Ar3carbonylamino, Het-carbonylamino, Ar3(CH2)ncarbonylamino, Het-(CH2)ncarbonylamino, and the other one of R2a and R2b is hydrogen; in case R2a is hydrogen, then R3 is hydrogen; in case R2b is hydrogen, the R3 is hydrogen or C1-6alkyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.
    本发明涉及对呼吸道合胞病毒复制具有抑制活性的5-或6-取代苯并咪唑衍生物,其具有���下式(I)的结构:一种前药、N-氧化物、加成盐、季铵盐、金属配合物或其立体化异构体,其中Q为Ar2、R6、用R6取代的吡咯烷基、用R6取代的哌啶基或用R6取代的环己胺基,G为直链键或可选择取代的C1-10烷二基;R1为Arl或单环或双环杂环;R2a和R2b中的一个为氰基C1-6烷基、氰基C2-6烯基、Ar3C1-6烷基、Het-C1-6烷基、N(R8aR8b)C1-6烷基、Ar3C2-6烯基、Het-C2-6烯基、Ar3氨基C1-6烷基、Het氨基C1-6烷基、Ar3硫基C1-6烷基、Het-硫基C1-6烷基、Ar3磺酰基C1-6烷基、Het-磺酰基C1-6烷基、Ar3氨基羰基、Het-氨基羰基、Ar3(CH2)n氨基羰基、Het-(CH2)n氨基羰基、Ar3羰基氨基、Het-羰基氨基、Ar3(CH2)n羰基氨基、Het-(CH2)n羰基氨基,R2a和R2b中的另一个为氢;如果R2a为氢,则R3为氢;如果R2b为氢,则R3为氢或C1-6烷基。本发明还涉及它们的制备和包含它们的组合物,以及它们作为药物的用途。
  • [EN] CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES<br/>[FR] ARYLALKYLAMINES MODULANT UN RECEPTEUR CALCIQUE
    申请人:AMGEN INC
    公开号:WO2003099776A1
    公开(公告)日:2003-12-04
    The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    该发明的化合物由以下一般结构(I)或其药用可接受盐所代表,以及含有它们的组合物,其中变量在此处定义,并且它们的用途是减少或抑制PTH分泌,包括减少或抑制PTH分泌的方法以及用于治疗或预防与骨骼疾病相关的疾病的方法,例如骨质疏松症,或与PTH过度分泌相关的疾病,例如甲状旁腺功能亢进症。该主题发明还涉及制备此类化合物的过程,以及在此类过程中有用的中间体。
  • [EN] AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION<br/>[FR] AMINOBENZIMIDAZOLES ET BENZIMIDAZOLES UTILISES EN TANT QU'INHIBITEURS DE LA REPLICATION DU VIRUS SYNCYTIAL RESPIRATOIRE
    申请人:TIBOTEC PHARM LTD
    公开号:WO2005058869A1
    公开(公告)日:2005-06-30
    Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula (I) the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; wherein G is a direct bond or C1-10alkanediyl optionally substituted with one or more hydroxy, C1-6alkyloxy, Ar1Cl-6alkyloxy, C1-6alkylthio, Ar1C1-6alkylthio, HO(-CH2-CH2-O)n-, C1-6alkyloxy(-CH2-M2-O)n- or Ar1Cl-6alkyloxy(-CH2-C2-O)n-; R1 is Ar1 or a monocyclic or bicyclic heterocycle; Q is hydrogen, amino or mono- or di(C1-4alkyl)amino; one of R2a and R3a is selected from halo, optionally mono- or polysubstituted C1-6alkyl, optionally mono- or polysubstituted C2-6alkenyl, nitro, hydroxy, Ar2, N(R4aR4b), N(R4aR4b)sulfonyl, N(R4aR4b)carbonyl, C1-6alkyloxy, Ar2oxy, Ar2C1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, or -C(=Z)Ar2; and the other one of R2a and R3a is hydrogen; in case R2a is different from hydrogen then R2b is hydrogen, C1-6alkyl or halogen and R3b is hydrogen; in case R3a is different from hydrogen then R3b is hydrogen, C1-6alkyl or halogen and R2b is hydrogen. Compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.
    氨基苯并咪唑和对RSV复制具有抑制活性的苯并咪唑,其具有式(I)的前药、N-氧化物、加合盐、季铵盐、金属配合物和立体化学异构体形式;其中G是直接键或C1-10烷二基,可选地取代一个或多个羟基、C1-6烷氧基、Ar1Cl-6烷氧基、C1-6烷基硫氧基、Ar1C1-6烷基硫氧基、HO(-CH2-CH2-O)n-、C1-6烷氧基(-CH2-M2-O)n-或Ar1Cl-6烷氧基(-CH2-C2-O)n-;R1是Ar1或单环或双环杂环;Q是氢、氨基或单或双(C1-4烷基)氨基;R2a和R3a中的一个选择自卤素、可选地单或多取代的C1-6烷基、可选地单或多取代的C2-6烯基、硝基、羟基、Ar2、N(R4aR4b)、N(R4aR4b)磺酰基、N(R4aR4b)羰基、C1-6烷氧基、Ar2氧基、Ar2C1-6烷氧基、羧基、C1-6烷氧羰基或-C(=Z)Ar2;R2a和R3a中的另一个是氢;如果R2a不同于氢,则R2b是氢、C1-6烷基或卤素,而R3b是氢;如果R3a不同于氢,则R3b是氢、C1-6烷基或卤素,而R2b是氢。含有这些化合物作为活性成分的组合物以及制备这些化合物和组合物的方法。
查看更多